RxSight Q3 EPS $(0.19) Beats $(0.43) Estimate, Sales $22.20M Beat $20.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
RxSight reported Q3 losses of $(0.19) per share, beating the analyst consensus estimate of $(0.43) by 55.81%. This is a 62% increase over losses from the same period last year. The company also reported quarterly sales of $22.20 million, beating the analyst consensus estimate of $20.55 million by 8.02%. This is a 75.97% increase over sales from the same period last year.
November 09, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RxSight's Q3 results beat analyst estimates, with losses improving and sales increasing significantly YoY. This could potentially boost investor confidence.
RxSight's Q3 results exceeded analyst estimates, with losses improving by 62% and sales increasing by 75.97% compared to the same period last year. This positive financial performance could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100